Evidence map›Paper›PMID 23860588›Full record

SynthesisNeuroepidemiology2013

Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature.

A Chiò, G Logroscino, B J Traynor, J Collins, J C Simeone, L A Goldstein, L A White

3 registry-linked trialsOpen access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neuroepidemiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 364 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
364citing papers in PubMed, 14 pooled it
28.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01984814 phase2withdrawnnot on this map

The Effect of Autologous Bone Marrow Mononuclear Cell Transplantation on the Survival Duration in Amyotrophic Lateral Sclerosis - A Retrospective Control Study

TypeinterventionalSponsorNeurogen Brain and Spine InstituteRan2008 to 2013Enrolled0ConditionsAmyotrophic Lateral SclerosisArmsStem cell
NCT02714036 phase1 / phase2completednot on this mapstarted 2016, after this paper: background citation

A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

TypeinterventionalSponsorMediciNovaRan2016 to 2020Enrolled35ConditionsAmyotrophic Lateral SclerosisArmsibudilast, Ibudilast
NCT02869048 unknown statusnot on this mapstarted 2016, after this paper: background citation

Amyotrophic Lateral Sclerosis and the Innate Immune System

TypeobservationalSponsorRigshospitalet, DenmarkRan2016 to 2026Enrolled375ConditionsAmyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
3 · Its place in the literature

Who cites it

364 citing papers in PubMed, 14 syntheses or guidelines pooled it, 824 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  11. The economic burden of amyotrophic lateral sclerosis: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2021
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Article
  18. Tofersen Treatment inMayo Clinic proceedings. Innovations, quality & outcomes · 2026
    Article
  19. Article
  20. Article

304 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

A ChiòRita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy. adriano.chio@unito.it
G Logroscino
B J Traynor
J Collins
J C Simeone
L A Goldstein
L A White
United BioSource Corporation (United Kingdom) · GBBiogen (United States) · USNational Institute on Aging · USUniversity of Bari Aldo Moro · ITUniversity of Turin · IT

Funding

Genome wide SNP analysis in Amyotrophic Lateral SclerosisZIAAG000933 · NIA · NATIONAL INSTITUTE ON AGING · PI TRAYNOR, BRYAN · 2009 to 2025
$9.8M
Intramural NIH HHS ZIA AG000933
6 · The paper itself

Abstract

backgroundAmyotrophic lateral sclerosis (ALS) is relatively rare, yet the economic and social burden is substantial. Having accurate incidence and prevalence estimates would facilitate efficient allocation of healthcare resources.

objectiveTo provide a comprehensive and critical review of the epidemiological literature on ALS.

methodsMEDLINE and EMBASE (1995-2011) databases of population-based studies on ALS incidence and prevalence reporting quantitative data were analyzed. Data extracted included study location and time, design and data sources, case ascertainment methods and incidence and/or prevalence rates. Medians and interquartile ranges (IQRs) were calculated, and ALS case estimates were derived using 2010 population estimates.

resultsIn all, 37 articles met the inclusion criteria. In Europe, the median incidence rate (/100,000 population) was 2.08 (IQR 1.47-2.43), corresponding to an estimated 15,355 (10,852-17,938) cases. Median prevalence (/100,000 population) was 5.40 (IQR 4.06-7.89), or 39,863 (29,971-58,244) prevalent cases.

conclusionsDisparity in rates among ALS incidence and prevalence studies may be due to differences in study design or true variations in population demographics such as age and geography, including environmental factors and genetic predisposition. Additional large-scale studies that use standardized case ascertainment methods are needed to more accurately assess the true global burden of ALS.

Indexed as

Global HealthAmyotrophic Lateral SclerosisHumans

Identifiers

PMID23860588
PMCPMC4049265
OpenAlexW2072204165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.